AbbVie Says IRS Can't Treat $1.6B Break Fee As Capital Loss

By Kevin Pinner · June 18, 2024, 4:38 PM EDT

The Internal Revenue Service cannot reclassify as a capital loss a $1.6 billion payment AbbVie made to an Irish biotechnology company after their failed merger and thereby raise the pharmaceutical giant's...

To view the full article, register now.